Lexaria Bioscience 's Cash & cash equivalent grew by 2478.19 % in the Q3 2026 sequentially, faster than Current Liabilities, this led to improvement in Lexaria Bioscience 's Quick Ratio to 5.2, Quick Ratio remained below Lexaria Bioscience Corp average.

Within Major Pharmaceutical Preparations industry 182 other companies have achieved higher Quick Ratio than Lexaria Bioscience in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 680, from total ranking in the second quarter 2026 at 1915.

Explain Quick Ratio?
How much Cash & cash equivalents LEXX�s has?
What are LEXX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/LEXX/financial-strength

https://api.csimarket.com/api/v1/companies/LEXX/fundamentals

https://api.csimarket.com/api/v1/companies/LEXX/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

LEXX Quick Ratio	(May 31 2026) Q3	(Feb 28 2026) Q2	(Nov 30 2025) Q1	(Aug 31 2025) Q4	(May 31 2025) Q3
Y / Y Current Liabilities Change	-51.95 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	10758.98 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	5.2	Subscribe	Subscribe	Subscribe	Subscribe
LEXX's Total Ranking	# 680	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	283.68 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	2478.19 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 183
Healthcare Sector	# 291
Overall Market	# 680

Quick Ratio Statistics
High	Average	Low
103.18	14.92	0.01
(Nov 30 2021)		(Jul 31 2012)

Financial Statements
Lexaria Bioscience 's Current Liabilities	$ 1 Millions	Visit LEXX's Balance sheet
Lexaria Bioscience 's Cash & cash equivalent	$ 4 Millions	Visit LEXX's Balance sheet
Source of LEXX's Sales		Visit LEXX's Sales by Geography

Cumulative Lexaria Bioscience 's Quick Ratio

LEXX's Quick Ratio for the trailling 12 Months

LEXX Quick Ratio	(May 31 2026) 12 Months	(Feb 28 2026) 12 Months	(Nov 30 2025) 12 Months	(Aug 31 2025) 12 Months	(May 31 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-29.38 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	1777.99 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	1.08	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3956	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-16.59 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	713.82 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to LEXX Financial Strength Comparisons >> Go to Compare LEXX Quick Ratio to its Competitors

On the trailing twelve months basis LEXX Cash & cash equivalent more than doubled by 10758.98 % in Q3 2026 year on year, while Current Liabilities more than doubled to $1 millions, this led to increase in in Lexaria Bioscience 's Quick Ratio to 1.08, Quick Ratio remained below LEXX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 433 other companies have achieved higher Quick Ratio than Lexaria Bioscience . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3238 to 3956.

Explain Quick Ratio?
How much Cash & cash equivalents LEXX�s has?
What are LEXX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 434
Healthcare Sector	# 889
Within the Market	# 3956

trailing twelve months Quick Ratio Statistics
High	Average	Low
50.59	10.92	0.03
(Feb 28 2022)		(Jan 31 2014)

Companies with similar Quick Ratio in the quarter ending May 31 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	May 31 2026 MRQ Cash & cash equivalent	May 31 2026 MRQ Current Liabilities
Canton Strategic Holdings Inc	14.18	$ 37.242 Millions	$ 2.626 Millions
An2 Therapeutics Inc	14.04	$ 78.387 Millions	$ 5.585 Millions
Aclaris Therapeutics Inc	13.97	$ 394.443 Millions	$ 28.241 Millions
Pmv Pharmaceuticals Inc	13.85	$ 146.393 Millions	$ 10.568 Millions
Generate Biomedicines Inc	13.76	$ 779.456 Millions	$ 56.636 Millions
Braveheart Bio, Inc.	13.56	$ 122.831 Millions	$ 9.058 Millions
First Tracks Biotherapeutics Inc	13.50	$ 168.018 Millions	$ 12.447 Millions
Arrivent Biopharma inc	13.41	$ 373.401 Millions	$ 27.844 Millions
Cogent Biosciences Inc	13.36	$ 792.300 Millions	$ 59.296 Millions
Aprea Therapeutics Inc	13.33	$ 41.233 Millions	$ 3.092 Millions
Polaryx Therapeutics Inc	13.22	$ 11.542 Millions	$ 0.873 Millions
Monopar Therapeutics Inc	13.14	$ 52.758 Millions	$ 4.016 Millions
Lexicon Pharmaceuticals Inc	12.96	$ 190.610 Millions	$ 14.706 Millions
Korro Bio Inc	12.89	$ 162.805 Millions	$ 12.628 Millions
Atea Pharmaceuticals Inc	12.89	$ 362.382 Millions	$ 28.124 Millions
Oric Pharmaceuticals Inc	12.76	$ 264.761 Millions	$ 20.756 Millions
Diamedica Therapeutics Inc	12.42	$ 81.875 Millions	$ 6.594 Millions
Vtv Therapeutics Inc	12.35	$ 86.643 Millions	$ 7.017 Millions
Theravance Biopharma inc	12.30	$ 378.546 Millions	$ 30.766 Millions
Coya Therapeutics Inc	12.29	$ 43.181 Millions	$ 3.512 Millions
Bridgebio Oncology Therapeutics Inc	12.28	$ 634.167 Millions	$ 51.634 Millions
Ocular Therapeutix Inc	12.17	$ 598.641 Millions	$ 49.174 Millions
Wave Life Sciences Ltd	12.07	$ 613.194 Millions	$ 50.815 Millions
Amylyx Pharmaceuticals Inc	11.86	$ 250.760 Millions	$ 21.150 Millions
Moonlake Immunotherapeutics	11.83	$ 537.000 Millions	$ 45.392 Millions
Eledon Pharmaceuticals Inc	11.77	$ 170.753 Millions	$ 14.503 Millions
Tyra Biosciences Inc	11.76	$ 354.060 Millions	$ 30.106 Millions
Opus Genetics Inc	11.69	$ 88.912 Millions	$ 7.605 Millions
Aardvark Therapeutics Inc	11.57	$ 73.921 Millions	$ 6.387 Millions
Dyne Therapeutics Inc	11.51	$ 898.475 Millions	$ 78.029 Millions

Date modified: 2026-10-15T05:23:37+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.